凝血酶/抗凝血酶復(fù)合體(TAT)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Thrombin/Antithrombin Complex (TAT)
- 編號SEA831Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3h
- 檢測范圍1.56-100pg/mL
- 靈敏度最小可檢測劑量小于等于0.70pg/mL.
- 樣本類型plasma
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 2352 ¥ 3360 ¥ 15120 ¥ 28560 ¥ 235200
- 欲了解實(shí)際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測凝血酶/抗凝血酶復(fù)合體(TAT)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的凝血酶/抗凝血酶復(fù)合體(TAT)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| sodium citrate plasma(n=5) | 81-90 | 86 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的凝血酶/抗凝血酶復(fù)合體(TAT)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中凝血酶/抗凝血酶復(fù)合體(TAT)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| sodium citrate plasma(n=5) | 94-101% | 90-101% | 90-104% | 90-98% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將凝血酶抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的TAT與連接于固相載體上的抗體結(jié)合，然后加入生物素化的抗凝血酶Ш抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的TAT呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計(jì)算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| EPA831Hu61 | 凝血酶/抗凝血酶復(fù)合體(TAT)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA831Hu01 | 凝血酶/抗凝血酶復(fù)合體(TAT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| MAA831Hu21 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB |
| MAA831Hu24 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA831Hu25 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA831Hu22 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA831Hu23 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA831Hu27 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA831Hu | 凝血酶/抗凝血酶復(fù)合體(TAT)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA831Hu | 凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| IUBMB LIFE | Genetic repression of mouse VEGF expression regulates coagulation cascade. [PubMed: 21086498] |
| Thrombosis Research | Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice [ScienceDirect: S0049384811004166] |
| Journal of Thrombosis and Haemostasis | High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality [Wiley: source] |
| 3 | Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling [Nature: 20120329] |
| Am J Respir Cell Mol Bio | Prolonged Exposure to Sphingosine 1–Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung Injury [PubMed: PMC2993087] |
| PLoS One | Host Defense Peptides of Thrombin Modulate Inflammation and Coagulation in Endotoxin-Mediated Shock and Pseudomonas aeruginosa Sepsis [PubMed: PMC3521733] |
| Haemetology | Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India [Pubmed: 23992124] |
| Am J Transl Res. | Selected hemostatic parameters in patients with pancreatic tumors. [Pubmed:Pmc4297344] |
| PLOS ONE | TFPI1 Mediates Resistance to Doxorubicin in Breast Cancer Cells by Inducing a Hypoxic-Like Response [Pubmed:24489651] |
| Leukemia | Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs) [Pubmed:24667943] |
| Anesthesia & Analgesia | Thrombomodulin Improved Liver Injury, Coagulopathy, and Mortality in an Experimental Heatstroke Model in Mice [Pubmed:24781566] |
| Cell Transplantation | Evidence of a Pivotal Role for the Distal Part of the Complement Cascade in the Diurnal Release of Hematopoietic Stem Cells Into Peripheral Blood [Pubmed:26087465] |
| European Journal of Pharmacology | (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coaCavia (Guinea pig )lation [Pubmed:27343380] |
| J Thromb Haemost. | Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis. [pubmed:27813324] |
| Blood Cells, Inflammation and Infection | Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injury [pubmed:29202212] |
| SCIENCE TRANSLATIONAL MEDICINE | Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension [pubmed:28148841] |
| 32 | Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target [pubmed:28289017] |
| Thrombosis?andHaemostasis | Nebulized anti-coagulants as a therapy for acute lung injury and acute respiratory distress syndrome [Pubmed: 29202212] |
| Thrombosis Research | The circadian rhythm of selected parameters of the hemostasis system in healthy people [] |
| Experimental Neurobiology | Transduced Tat-aldose Reductase Protects Hippocampal Neuronal Cells against Oxidative Stress-induced Damage [Pubmed: 31698553] |
| LIVER TRANSPLANTATION | The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia‐reperfusion injury in mice [Pubmed: 33108682] |
| Am J Physiol Heart Circ Physiol | Doxorubicin contributes to thrombus formation and vascular injury via enhancing platelet functions in vivo [Pubmed: 32469636] |
| Intensive Care Medicine Experimental | Preservation of renal endothelial integrity and reduction of renal edema by aprotinin does not preserve renal perfusion and function following experimental?… [34169407] |
| Intensive Care Med Exp | Complement factor D is linked to platelet activation in human and rodent sepsis [34396466] |
